OncoMatch

OncoMatch/Clinical Trials/NCT06807606

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

Is NCT06807606 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for hematologic malignancies.

Phase 2RecruitingM.D. Anderson Cancer CenterNCT06807606Data as of Jun 2026

Treatment: Drugs Cyclophosphamide · Fludarabine · Thiotepa · Tacrolimus · Mycophenolate mofetilThe goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control high-risk hematological malignancies in patients who need a second allogeneic stem cell transplantation.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

Drugs CyclophosphamideFludarabineThiotepa

Other

TacrolimusMycophenolate mofetil

Cancer type

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Non-Hodgkin Lymphoma

Multiple Myeloma

Myelodysplastic Syndrome

Chronic Lymphocytic Leukemia

Demographics

Ages 0–60

Prior therapy

Must have received: stem cell transplant — allogeneic

Lab requirements

Kidney function

Calculated creatinine clearance > 50 ml/min

Liver function

Bilirubin < 2 mg/dL (unless benign congenital hyperbilirubinemia or hemolysis); ALT < 5 x upper limit of normal (ULN)

Cardiac function

Left ventricular ejection fraction (MOD-bp) > 50%

Calculated creatinine clearance > 50 ml/min. Bilirubin < 2 mg/dL (unless benign congenital hyperbilirubinemia or hemolysis). ALT < 5 x upper limit of normal (ULN). Left ventricular ejection fraction (MOD-bp) > 50%.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • The University of Texas M. D. Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06807606 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received stem cell transplant.

Is there an age limit?

Yes. Patients must be 60 years or younger and at least 0 years old.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify